Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient
CeriBell, Inc. Common Stock · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · Now $17.61
+12% in 7d after detection
Post-detection moves
1h
—
1d
+6.9%
3d
-2.7%
7d
+12%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS